Diethylolglycine Veterinary Grade API (N,N-bis(2-hydroxyethyl)glycine; CAS 150-25-4, C₆H₁₃NO₄, molecular weight 163.17 g/mol, pKₐ 8.35 at 25 °C) is handled differently across downstream veterinary dosage forms because the controlling process variables are not equivalent: compaction behaviour in tablets, sterility and particulate control in injectables, powder flow and segregation in capsules, reconstitution stability in oral powders, homogeneity in feed premixes, granule size distribution in sachets, and pH/preservative balance in oral solutions. The following application scenarios separate these routes by process boundary rather than by generic excipient lists.

Direct Compression Tablets Require Moisture, Flow, and Compaction Profiling

For direct compression, Diethylolglycine Veterinary Grade API presents two technical barriers: low bulk density and moisture uptake above 60% RH. The incoming API is conditioned at ≤ 45% RH, de-lumped through a 500 µm sieve, and then blended with low-moisture excipients. A representative starting formulation contains active substance 10–30 wt%, microcrystalline cellulose PH 102 25–40 wt%, spray-dried lactose monohydrate 20–40 wt%, crospovidone 2–5 wt%, colloidal silicon dioxide 0.25–0.50 wt%, and sodium stearyl fumarate 0.5–1.0 wt%. The active substance mass fraction is fixed by the registered veterinary dose and is not a processing variable. Blending is performed in a bin blender at 60–70% vessel fill volume and 25 rpm for 20–30 min; extension beyond 45 min can reduce tablet hardness by 15–20% because sodium stearyl fumarate coats the filler particles and delays bonding. On a high-speed rotary press with 10-mm round concave tooling, compression force is typically maintained between 6 kN and 12 kN. The target hardness window is 60–90 N, friability is kept below 1.0% per Ph. Eur. 2.9.7, and weight variation is controlled to an acceptance value ≤ 15 under USP <905>. Final tablets are sealed in cold-form aluminium blisters because moisture ingress above 0.5 mg/day under accelerated conditions can initiate surface speckling and hardness loss. Disintegration is tested in purified water at 37 ± 2 °C by USP <701> or Ph. Eur. 2.9.1, with a typical limit of ≤ 15 min for uncoated tablets.

What Changes When Diethylolglycine Is Processed into a Terminal-Sterilised Solution?

In parenteral formulation, the controlling variable shifts from compaction mechanics to aqueous stability, sterility, and particulate cleanliness. The API is dissolved in Water for Injection at 20–35 °C under nitrogen overlay; the concentration is fixed by the marketing authorisation, and published data for this specific veterinary grade under terminal sterilisation is limited. pH is adjusted with 0.1 M hydrochloric acid or sodium hydroxide to the registered range, usually 6.0–7.5, because the zwitterionic buffer behaviour of diethylolglycine changes with ionic strength and can drift during autoclaving. Tonicity is corrected with sodium chloride to approximately 290 mOsm/kg measured by freezing point depression per Ph. Eur. 2.2.35. The solution is clarified through a 0.45 µm PVDF membrane and sterile-filtered through a 0.22 µm membrane before filling into Type I borosilicate glass vials. Where aqueous degradation is below the qualification threshold, terminal sterilisation at 121 °C for 15 min is used; if total unknown impurities exceed 0.01%, the process is moved to aseptic filtration. Release testing includes sterility per Ph. Eur. 2.6.1 or USP <71>, bacterial endotoxins per Ph. Eur. 2.6.14 with a dose-based limit, sub-visible particles per Ph. Eur. 2.9.19 or USP <788>, and container closure integrity per USP <1207>. The terminal product is an injectable solution in amber glass when photostability testing per VICH GL5 indicates measurable light degradation.

Because the dose is low and the active substance must be isolated from ambient moisture, hard gelatin capsule filling for Diethylolglycine Veterinary Grade API is selected over direct compression when compressibility is poor or when multiple strengths are required from one blend. The API is first sieved with lactose monohydrate through a 355 µm screen and then mixed with pregelatinised maize starch, sodium starch glycolate, colloidal silicon dioxide, and magnesium stearate. A representative capsule formulation contains active substance 5–20 wt%, lactose monohydrate 45–65 wt%, pregelatinised starch 15–25 wt%, sodium starch glycolate 2–4 wt%, colloidal silicon dioxide 0.25–0.50 wt%, and magnesium stearate 0.5–1.0 wt%, with the diluent fraction adjusted so that the final fill mass falls within the capacity of a size 1 or size 0 capsule. On a tamping-pin capsule machine, powder bed height is maintained at 30–50 mm; tamping force is set low enough to avoid plug lamination but high enough to produce weight consistency. Fill weight variation is measured by USP <905> and should give an acceptance value ≤ 15. Processing humidity is held at ≤ 45% RH, and empty hard gelatin capsules are conditioned at 15–20 °C and 40–50% RH before loading to prevent shell brittleness. Microbial quality is controlled by Ph. Eur. 5.1.4. If the API is hygroscopic above 60% RH, a desiccant pouch is sealed into the HDPE container. The terminal product is a hard capsule for oral administration to livestock or companion animals, with storage at or below 25 °C and protection from light.

Oral Powder Reconstitution and Sachet Dosing Parameters

When the target species cannot be dosed with tablets or capsules, oral powders are used to allow bodyweight-adjusted dosing. Diethylolglycine Veterinary Grade API is converted into a free-flowing powder by geometric dilution with a water-soluble carrier. A representative formulation contains active substance 10–25 wt%, sucrose or sorbitol 65–80 wt%, anhydrous citric acid 0.5–2.0 wt%, sodium citrate dihydrate 0.2–1.0 wt%, xanthan gum 0.1–0.3 wt%, and a permitted flavour 0.1–0.5 wt%. Sorbitol is preferred when the target species has known sucrose intolerance. Blending is performed in a ribbon blender at 60–70% fill volume for 15–20 min; the API is first triturated with an equal mass of carrier to eliminate active-rich pockets and then diluted in 1:1 incremental steps. Particle size is controlled to d90 ≤ 355 µm by laser diffraction per Ph. Eur. 2.9.31, which reduces sachet fill variation and improves reconstitution. Sachet filling uses a volumetric auger filler; fill weight variation is kept within ± 5% of target, and seal integrity is tested by vacuum leak. The terminal product is packed in paper/aluminium/PE sachets and reconstituted with potable or purified water at 20–25 °C; the resulting solution is used within 24 h unless preserved. Published stability data for this specific veterinary grade in hard water or chlorinated drinking water are limited, so the reconstitution vehicle is usually softened or purified water.

When the Compound Is Added to a Medicated Feed Premix, Homogeneity Depends on Carrier Pre-Coating

Medicated premix manufacture imposes strict cross-contamination and homogeneity limits because Diethylolglycine Veterinary Grade API is dispersed into a feed matrix at low mass fractions. The active substance is first de-agglomerated and adhered to a carrier such as calcium carbonate, wheat middlings, or lactose by spraying with edible vegetable oil at 1–2 wt% of premix mass. This pre-coating reduces dust generation and prevents segregation during transfer. The API-to-carrier ratio in the intermediate premix is often 1:10 to 1:100; the final feed concentration is set by the veterinary prescription, commonly in the range of 10–100 mg/kg for non-antibiotic actives in complete feed, but no universal limit applies. The pre-blend is introduced into a ribbon mixer at 70–80% vessel fill and mixed for 10–15 min at 20–30 rpm. Homogeneity is validated by taking 10 samples across the discharge and calculating the coefficient of variation of active content. The batch is acceptable when the CV is ≤ 5% and all samples fall within 90–110% of label claim, in accordance with the medicated feed requirements of Regulation EU 2019/4. If the CV remains above 5%, corrective actions include increasing the oil pre-coat to 2 wt%, reducing carrier particle size to d50 ≤ 200 µm, or extending mixing by 2–3 min. Clean-out between batches is verified by swab recovery and rinsate testing. The terminal product is a dust-free, free-flowing premix packed in 25 kg paper sacks with an inner PE liner, labelled with the active concentration, target species, and withdrawal period if applicable.

In granule production for sachet or bottle dosing, damp granulation converts Diethylolglycine Veterinary Grade API into dense free-flowing granules, and all process decisions follow from the need to keep granule residual moisture below 1.5% without exposing the molecule to prolonged heat. The dry mix contains active substance 10–30 wt%, lactose monohydrate 30–50 wt%, maize starch 10–20 wt%, povidone K30 2–5 wt%, and croscarmellose sodium 1–3 wt%. The blend is granulated in a high-shear mixer with impeller speed 150–250 rpm and chopper speed 1500–2000 rpm; granulation liquid is purified water or a 30–50% ethanol-water mixture added over 3–5 min. Endpoint is judged by torque and mass consistency, not by fixed time alone; overwet batches produce hard granules that resist milling, while underwet batches generate excessive fines. The wet mass is dried in a fluid-bed drier with inlet air at 50–70 °C until loss on drying is ≤ 2.0%, then milled through an oscillating granulator fitted with a 0.8–1.0 mm screen. Fines below 75 µm are kept below 15% of granule mass to avoid flow stoppage in dosing equipment. The granules are filled into aluminium foil laminate sachets under nitrogen; fill weight variation is checked by USP <905> with an acceptance value ≤ 15. The terminal product is an oral granule for administration in feed or after reconstitution, with storage limited to 25 °C unless a stability study supports broader conditions. Published data for this specific veterinary grade in fluid-bed granulation scale-up are limited, so pilot-scale factorial design is recommended before transfer to production.

For drinking water administration, liquid oral solutions are prepared when the API is sufficiently soluble and the target species requires flexible dosing by drench or proportional water medication. The active substance is dissolved in purified water at 25–35 °C; because diethylolglycine has a pKₐ near 8.35 at 25 °C, pH adjustment with citric acid or sodium hydroxide is used to reach the registered pH and to prevent precipitation during storage. A maintained oral solution often contains active substance 1–10 wt%, glycerin 5–15 wt% as a co-solvent and sweetness carrier, potassium sorbate 0.1–0.2 wt%, sodium benzoate 0.05–0.10 wt%, disodium edetate 0.02–0.05 wt%, and purified water to final mass. Preservative efficacy is verified by Ph. Eur. 5.1.3 or USP <51>; if the system fails at the lower concentration, the batch is reformulated rather than increasing the active load. The solution is clarified through a 5 µm or 1 µm filter and filled into amber HDPE or glass bottles; amber packaging is selected when photostability testing per VICH GL5 indicates light-induced degradation. Filling is conducted at 20–25 °C to avoid viscosity changes, and in-line fill volume is checked every 30 min against the container fill volume tolerance of Ph. Eur. or USP. The terminal product is an oral solution for direct drenching or dilution in drinking water, with an in-use stability period supported by the dossier after first opening or reconstitution. Particular attention is given to pH drift: a fall below the registered pH can increase ionised fraction and reduce palatability, while a rise above the registered pH can support microbial growth if the preservative is pH-dependent.